Why Is JOHNSON & JOHNSON (JNJ) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 22, 2026 at 12:12 PM ET · reviewed against 20 wire stories
JOHNSON & JOHNSON (JNJ) is drawing unusual attention today. Our newswire has captured 20 stories on JNJ across 12 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Johnson & Johnson (JNJ) stock is moving higher today as the company received U.S. Food and Drug Administration authorization for its Ottava robotic surgical system. The approval marks a milestone in the company’s expansion into robotic surgery and has driven the stock up more than 2.2% as of the latest trade. The Ottava system is the first table-integrated soft-tissue robotic surgical system authorized for multiple general surgery procedures, including gastric bypass and appendectomy.
What Happened
The FDA granted De Novo authorization for the Ottava robotic surgical system, a development that has positioned Johnson & Johnson as a key player in the next phase of robotic-assisted surgery. The Ottava system is designed to offer improved precision and flexibility in general surgery. The company plans to commercially launch the system with select U.S. customers while pursuing additional indications. Analysts from Guggenheim and Raymond James have reiterated or raised their price targets for JNJ in recent weeks, signaling confidence in the company’s long-term potential.
What The Data Shows
The stock opened at $252.22, up 0.6% from the previous close, and reached an intraday high of $256.29 before settling at $255.79. Trading volume has been muted at 1.6 million shares, or 20% of the 3-month daily average. Over the past eight sessions, the stock has declined 1.1% from $257.90 to $255.12. The stock is currently trading within its 52-week range of $162.78 to $269.43. Additionally, the stock printed one notable options trade, a call premium of $425,000, with no put activity recorded.
What To Watch
Johnson & Johnson is scheduled to report first-quarter 2026 earnings on July 24. Analysts are forecasting adjusted earnings per share of $2.69 and revenue of $23.66 billion. The company’s recent insider and congressional transactions, as well as the broader healthcare sector’s performance, will also be key factors to monitor.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
JNJ · Jul 27 session (5-min) · +2.51% vs prior close · updated 8:05 PM ETAI sentiment, last 36h · averaged over 20 stories · 53/100 neutral
The headlines behind the move
Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoMorningstarBULLISH 63M&A
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, including a $465 million equity investment, and additional contingent payments of $140 million if certain development milestones are achieved.
11h agoWSJBULLISH 56M&A
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
11h agoTipRanksBULLISH 63M&A
Johnson & Johnson Updates Guidance After Firefly, Sail Deals
An announcement from Johnson & Johnson ( ($JNJ) ) is now available. On July 29, 2026, Johnson & Johnson completed its $1 billion cash acquisition of Firefly Bio, In...
11h agoSeeking AlphaBULLISH 67M&A
Johnson & Johnson gets $2.58B option to acquire Sail in vivo CAR-T therapies push
Johnson & Johnson’s $2.58B Sail Biomedicines deal boosts in vivo CAR-T immunology pipeline; see key payments, milestones and EPS impact—read now.
11h agoBloombergBULLISH 63M&A
J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion
11h agoStockTitanBULLISH 62M&A
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation | JNJ Stock News
11h agoReutersBEARISH 38Earnings
Johnson & Johnson lowers 2026 profit forecast
11h agoStockTitanBULLISH 63Product/PR
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset | JNJ Stock News
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
But is that performance sustainable?
Frequently asked questions
Why is JNJ stock moving today?
JOHNSON & JOHNSON (JNJ) is drawing unusual attention today. Our newswire has captured 20 stories on JNJ across 12 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100). The most recent driver: "Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines" (Morningstar).
Is JNJ a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of JNJ coverage reads 53/100 over 20 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →